 |
|
|
| |
Failure to multiple Interferon-free direct Antiviral therapies: could Chronic hepatitis C become incurable?
|
| |
| |
Download the PDF here
Reported by Jules Levin
AASLD 2017 Wash DC October 20-24
Johannes Vermehren1, Julia Dietz1, Simone Susser1, Eckart Schott2, Jörn M. Schattenberg3, Eugen Zizer4, Julian Schulze zur Wiesch5, Christoph Antoni6, Perdita Wietzke-Braun7, Claus Niederau8, Stefan Mauss9, Jurgen K. Rockstroh10, Beat Mullhaupt11, Rudolf E. Stauber12, Stefan Zeuzem1, Christoph Sarrazin1,13; 1Medizinische Klinik 1,
Universitatsklinikum Frankfurt, Frankfurt am Main, Germany; 2Charité Universitatsmedizin Berlin, Berlin, Germany; 3Universitatsklinikum Mainz, Mainz, Germany; 4Universitatsklinikum Ulm, Ulm, Germany; 5Universitatsklinikum Eppendorf, Hamburg, Germany; 6Universitatsklinikum Mannheim, Mannheim, Germany; 7Universitatsklinikum Schleswig-Holstein, Kiel, Germany; 8Katholisches Klinikum Oberhausen, Oberhausen, Germany; 9Center for HIV and Hepatogastroenterology, Dusseldorf, Germany; 10Universitatsklinikum Bonn, Bonn, Germany; 11Universitatsspital Zurich, Zurich, Switzerland; 12Medizinische Universitat Graz, Graz, Austria; 13St Josefs Hospital, Wiesbaden, Germany
AASLD: Susceptibility to Voxilaprevir of NS3 Resistance-Associated Substitutions and Clinical Isolates From Direct-Acting Antiviral-Experienced and -Naïve Patients - (10/26/17)
AASLD: SOF/VEL/VOX for 12 Weeks in NS5A-Inhibitor-Experienced HCV-Infected Patients: Results of the Deferred Treatment Group in the Phase 3 POLARIS-1 Study - (10/23/17)
from Jules: I have attached the poster pdf so you can see a better context of this data. The poster shows straight across in a vertical context each patient's 1st DAA treatment, the resistance analysis after failing that, then the 2nd DAA treatment is shown straight across and the resistance analysis after that failure, and then the 3rd DAA pretreatment across in a straight line for each patient.
|
| |
|
|
|
|
|
